Payment overview · 2025
General Payments
$133.74
8 reported records · 7 companies
Healthcare provider profile · identity verified
William Lee Bell, MD
Allopathic & Osteopathic Physicians|Family Medicine · ROBBINS, NC · NPI 1619971694
Verified facts
What the public records show
CMS Open Payments records show William Lee Bell, MD received $133.74 in general payments during 2025 across 8 reported records.
Averitas Pharma Inc. accounted for 23.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $31.80 | 23.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.80 | 23.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.32 | 10.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.30 | 10.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.27 | 10.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.14 | 10.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.11 | 10.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $133.74 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $31.80 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 114 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
141 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
84 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
114 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
37 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 451 | 92 |
| Omeprazole | Omeprazole | 446 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 430 | 105 |
| Atorvastatin Calcium | Atorvastatin Calcium | 378 | 99 |
| Lisinopril | Lisinopril | 362 | 98 |
| Losartan Potassium | Losartan Potassium | 302 | 72 |
| Metformin Hcl | Metformin Hcl | 297 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 282 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 266 | 63 |
| Furosemide | Furosemide | 242 | 61 |
| Alprazolam | Alprazolam | 213 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 211 | 54 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 188 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 181 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 176 | 40 |
| Montelukast Sodium | Montelukast Sodium | 168 | 41 |
| Amitriptyline Hcl | Amitriptyline Hcl | 156 | 34 |
| Trazodone Hcl | Trazodone Hcl | 151 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 146 | 40 |
| Farxiga | Dapagliflozin Propanediol | 141 | 28 |
| Prednisone | Prednisone | 139 | 93 |
| Warfarin Sodium | Warfarin Sodium | 139 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 138 | 30 |
| Sertraline Hcl | Sertraline Hcl | 138 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 135 | 30 |
| Simvastatin | Simvastatin | 126 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 35 |
| Famotidine | Famotidine | 117 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 25 |
| Finasteride | Finasteride | 115 | 32 |
| Eliquis | Apixaban | 114 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 114 | 24 |
| Potassium Chloride | Potassium Chloride | 110 | 28 |
| Ozempic | Semaglutide | 105 | 16 |
| Cefdinir | Cefdinir | 96 | 76 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 95 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 89 | 69 |
| Glimepiride | Glimepiride | 89 | 19 |
| Allopurinol | Allopurinol | 85 | 25 |
| Jardiance | Empagliflozin | 84 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 19 |
| Pregabalin | Pregabalin | 78 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 19 |
| Mirtazapine | Mirtazapine | 74 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 71 | 52 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 12 |
| Celecoxib | Celecoxib | 70 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 70 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 69 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 11 |
| Atenolol | Atenolol | 62 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 17 |
| Spironolactone | Spironolactone | 60 | 13 |
| Fluconazole | Fluconazole | 59 | 33 |
| Carvedilol | Carvedilol | 58 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 17 |
| Donepezil Hcl | Donepezil Hcl | 56 | 13 |
| Promethazine Hcl | Promethazine Hcl | 56 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 14 |
| Ezetimibe | Ezetimibe | 54 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | 41 |
| Paroxetine Hcl | Paroxetine Hcl | 54 | 13 |
| Meclizine Hcl | Meclizine Hcl | 53 | 24 |
| Ventolin Hfa | Albuterol Sulfate | 51 | suppressed |
| Primidone | Primidone | 50 | 12 |
| Clonazepam | Clonazepam | 48 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 47 | suppressed |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Meloxicam | Meloxicam | 47 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 45 | suppressed |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Mupirocin | Mupirocin | 43 | 29 |
| Rizatriptan | Rizatriptan Benzoate | 43 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 43 | 19 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 19 |
| Estradiol | Estradiol | 38 | 11 |
| Ibuprofen | Ibuprofen | 38 | suppressed |
| Rybelsus | Semaglutide | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 37 | 37 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Cartia Xt | Diltiazem Hcl | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 20 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 21 |
| Colchicine | Colchicine | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Nystatin | Nystatin | 23 | 12 |
| Phenobarbital | Phenobarbital | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 22 |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | 11 |
| Invokana | Canagliflozin | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Mitigare | Colchicine | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | 11 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $133.74 · 8 records | Averitas Pharma Inc. | AIRSUPRA, BREZTRI, ELIQUIS, MOUNJARO, NEXLETOL, NURTEC ODT, QUTENZA, REXULTI, The Cologuard Plus Collection Kit, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error